A Phase 1, First in Human, Dose-Escalation Study of TORL-1-23 in Participants With Advanced Cancer
Who is this study for? Patients with Advanced Solid Tumor
What treatments are being studied? TORL-1-23
Status: Recruiting
Location: See all (14) locations...
Intervention Type: Drug
Study Type: Interventional
Study Phase: Phase 1
SUMMARY
This first-in-human study will evaluate the safety, tolerability, pharmacokinetics, and antitumor activity of TORL-1-23 in patients with advanced cancer
Eligibility
Participation Requirements
Sex: All
Minimum Age: 18
Healthy Volunteers: f
View:
• Advanced solid tumor
• Measurable disease, per RECIST v1.1
• Eastern Cooperative Oncology Group (ECOG) performance status 0-1
• Adequate organ function
Locations
United States
California
Providence Medical Foundation
RECRUITING
Fullerton
UCLA - JCCC Clinical Research Unit
RECRUITING
Los Angeles
Kentucky
University of Kentucky Medical Center
RECRUITING
Lexington
Minnesota
University of Minnesota
RECRUITING
Minneapolis
Mayo Clinic in Rochester
RECRUITING
Rochester
New York
Memorial Sloan Kettering Cancer Center
RECRUITING
New York
Ohio
Cleveland Clinic
RECRUITING
Cleveland
Texas
Sarah Cannon Research Institute Texas Oncology
RECRUITING
Tyler
Virginia
Virginia Cancer Specialists
RECRUITING
Fairfax
Other Locations
Republic of Korea
Asan Medical Center
RECRUITING
Seoul
Samsung Medical Center
RECRUITING
Seoul
Seoul National University Hospital
RECRUITING
Seoul
Severance Hospital
RECRUITING
Seoul
St. Vincent's Hospital, The Catholic University of Korea
RECRUITING
Suwon
Contact Information
Primary
Hatem Dokainish
hatem.dokainish@torlbio.com
310-348-9636
Backup
Ibrahim Qazi
310-348-9636
Time Frame
Start Date: 2021-11-17
Estimated Completion Date: 2026-11-15
Participants
Target number of participants: 90
Treatments
Experimental: Monotherapy Dose Finding - Part 1
TORL-1-23
Experimental: Expansion as Monotherapy - Part 2
TORL-1-23
Related Therapeutic Areas
Sponsors
Collaborators: Translational Research in Oncology
Leads: TORL Biotherapeutics, LLC